Crk-like protein mRNA (CRKL mRNA)

Crk-like protein (CRKL) mRNA encodes an adapter protein that is a critical component of intracellular signaling networks, particularly in hematopoietic and epithelial cells (UniProt: P46109). The CRKL protein contains SH2 and SH3 domains that facilitate the assembly of multi-protein complexes involved in cell adhesion, migration, and proliferation (NCBI Gene: 1399). In the context of disease, CRKL is the primary substrate of the BCR-ABL tyrosine kinase in chronic myeloid leukemia (CML), and its phosphorylation status is a gold-standard biomarker for monitoring the efficacy of tyrosine kinase inhibitors (TKIs) like imatinib (PubMed: 11069131). Targeting CRKL mRNA specifically using RNA interference (siRNA) or antisense oligonucleotides (ASOs) has emerged as a strategy to overcome TKI resistance and inhibit tumor growth in various cancers, including non-small cell lung cancer and pancreatic cancer (PubMed: 23460538). By reducing the levels of CRKL mRNA, these therapeutic approaches aim to disrupt the oncogenic signaling nodes that drive malignancy (PubMed: 25605114). Although clinical-stage mRNA-targeting drugs for CRKL are still in development, the target remains a high-priority focus for precision oncology due to its central role in bypass signaling pathways.

Other names

v-crk avian sarcoma virus CT10 oncogene homolog-like mRNACRK-like protein mRNACRKL transcript

RNA interference or antisense-mediated degradation of mRNA to prevent translation of the CRKL adapter protein.